Innovator companies should expect Orange Book patent listing challenges to emerge as an additional and simpler tool for ...

The investigation has been prompted by Teva’s refusal to take down about two dozen patents for its asthma and chronic obstructive pulmonary disorder (COPD) inhalers, according to a Washington Post ...

Teva’s asthma and COPD patents listed in the FDA’s Orange Book are under scrutiny and the company has until 24 July to adhere ...

According to "The Washington Post", the FTC claims that drug companies, among them Teva, made slight changes to their ...